Clinical Trials
88 trialsGEN3014 Trial in Relapsed or Refractory Hematologic Malignancies
Genmab
A Safety Study of PF-08046044/SGN-35C in Adults With Advanced Cancers
Seagen Inc.
A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers
Pfizer
MAPtivate-6
Pfizer
Study of VAY736 as Single Agent and in Combination With Select Antineoplastic Agents in Patients With Non-Hodgkin Lymphoma
Novartis
A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML
MEI Pharma, Inc.
A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Atara Biotherapeutics
A Safety Study of PF-08046045/SGN-35T in Adults With Advanced Cancers
Seagen Inc.
A Study of SAR444245 With or Without Other Anticancer Therapies for the Treatment of Adults and Adolescents With Relapsed or Refractory B Cell Lymphoma (Master Protocol) [Pegathor Lymphoma 205]
Sanofi
ELiPSE-1
Century Therapeutics, Inc.
Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
Incyte Corporation
A Study of bbT369 in Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma (NHL)
Regeneron Pharmaceuticals
Effects of Maplirpacept (PF-07901801),Tafasitamab, and Lenalidomide in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma
Pfizer
Safety and Efficacy of MAK683 in Adult Patients With Advanced Malignancies
Novartis
ALEXANDER
Autolus Limited
Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL
Biomea Fusion Inc.
A Study of the Safety, Tolerability and Effectiveness of EZM0414 (IPN60210) Investigative Product in Participants With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B Cell Lymphoma
Ipsen
GLEAN-1
Adicet Therapeutics
SWATCH
Antengene Corporation
FIRCE-1
CARGO Therapeutics
Evaluation of Safety and Efficacy of Allo GDA-201 Natural Killer (NK) Cells in Patients With Relapsed/Refractory B Cell NHL
Gamida Cell ltd
Connect® Lymphoma Disease Registry: A US-Based Prospective Observational Cohort Study
Celgene
NKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Relapsed/Refractory Large B-cell Lymphoma
Nektar Therapeutics
A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer
Seagen Inc.
An Efficacy and Safety Proof of Concept Study of Daratumumab in Relapsed/Refractory Mantle Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma
Janssen Research & Development, LLC
LOTIS-9
ADC Therapeutics S.A.
Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas
Zhejiang DTRM Biopharma
A Clinical Study of ONCT-808 in Subjects With Relapsed or Refractory B-Cell Malignancies
Oncternal Therapeutics, Inc
First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas
Genmab
A Dose Finding Study Followed by a Safety and Efficacy Study for Patients With Multiple Myeloma or Lymphoma
Taiho Oncology, Inc.
A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma
Pfizer
Long-term Follow-up Study in Patients Previously Treated With a Mustang Bio CAR-T Cell Investigational Product.
Mustang Bio
A Study of MS-553 in Patients With Relapsed or Refractory B-cell Lymphoma
MingSight Pharmaceuticals, Inc
A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax in Combination With Polatuzumab Vedotin Plus Rituximab (R) and Cyclophosphamide, Doxorubicin, Prednisone (CHP) in Participants With Untreated BCL-2 Immunohistochemistry (IHC)-Positive Diffuse Large B-Cell Lymphoma (DLBCL)
Hoffmann-La Roche
Phase 2 Study of Plamotamab Combined With Tafasitamab Plus Lenalidomide Versus Tafasitamab Plus Lenalidomide in Relapsed or Refractory (R/R) Diffuse Large-cell B-cell Lymphoma (DLBCL)
Xencor, Inc.
Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 562 in Subjects With r/r Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, or Follicular Lymphoma
Amgen
Study of BN301, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies
BioNova Pharmaceuticals (Shanghai) LTD.
Safety and Efficacy Study of Loncastuximab Tesirine + Ibrutinib in Diffuse Large B-Cell or Mantle Cell Lymphoma
ADC Therapeutics S.A.
Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma and Follicular Lymphoma
Celgene
A Phase I/II Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Rituximab in Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Philogen S.p.A.
PNT2258 for Treatment of Patients With Richter's Transformation (Brighton)
Sierra Oncology LLC - a GSK company
A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors
Asana BioSciences
Quality of Life of Adults With Diffuse Large B-cell Lymphoma Treated With Tisagenlecleucel
Pack Health
A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma
MEI Pharma, Inc.
Safety Study of SEA-CD40 in Cancer Patients
Seagen Inc.
MATCH
Antengene Corporation
A Study to Evaluate the Efficacy and Safety of Polatuzumab Vedotin in Combination With Bendamustine and Rituximab Compared With Bendamustine and Rituximab Alone in Chinese Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL).
Hoffmann-La Roche
TAK-659 in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Calithera Biosciences, Inc
Study to Evaluate Adverse Events, Change in Disease Activity, Movement of Oral ABBV-623 and ABBV-992 Tablets in the Body of Adult Participants With B-cell Cancers
AbbVie
Study of Tisagenlecleucel in Combination With Ibrutinib in r/r Diffuse Large B-cell Lymphoma Patients
Novartis